|Last 24 Hours:|
VolitionRx chief hails “wonderful” progress accomplished in 2016
Friday, March 10, 2017 7:41
% of readers think this story is Fact. Add your two cents.
(Before It's News)
PCameron Reynolds, chief executive at blood-based diagnostic tests company VolitionRx (NYSEMKT:VNRX), discusses the group’s full-year results with Proactive Investors.
Story by ProactiveInvestors